Pluristem Therapeutics Inc (PSTI)

1.12
NASDAQ : Health Care
Prev Close 1.13
Day Low/High 1.11 / 1.14
52 Wk Low/High 1.04 / 1.85
Avg Volume 383.30K
Exchange NASDAQ
Shares Outstanding 96.07M
Market Cap 108.55M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stocks Mixed Again as Dow Declines but Nasdaq Remains on Track for Record Close

Stocks Mixed Again as Dow Declines but Nasdaq Remains on Track for Record Close

Stocks turn mixed on Tuesday, though the Nasdaq remains on track to set to record a close for its third day in a row.

Stocks Turn Positive, Nasdaq Trades Above Record Closing High

Stocks Turn Positive, Nasdaq Trades Above Record Closing High

Stocks turn higher Tuesday as crude oil declines and the fourth-quarter earnings season draws closer.

Stock Futures Little Changed as Oil Prices Level Off

Stock Futures Little Changed as Oil Prices Level Off

Stock futures are little changed on Tuesday as investors await news from a press conference Wednesday with President-elect Donald Trump. Oil prices level off.

Pluristem CEO Zami Aberman Re-Elected To Alliance For Regenerative Medicine's Board Of Directors

Pluristem CEO Zami Aberman Re-Elected To Alliance For Regenerative Medicine's Board Of Directors

ARM is the Preeminent Global Advocate for the Advancement of Regenerative Medicine

Pluristem Participates In Radiation Injury Treatment Network Conference Co-sponsored By National Institutes Of Health's NIAID

Pluristem Participates In Radiation Injury Treatment Network Conference Co-sponsored By National Institutes Of Health's NIAID

Pluristem's PLX-R18 is being studied by NIAID for Acute Radiation Syndrome (ARS), and following pharmacodynamics, safety and efficacy trials, the company plans to initiate a pivotal study to gain approval for ARS via the FDA Animal Rule.